PSA isn’t the whole story: what men should know about prostate screening

When it comes to prostate cancer screening, one number can carry a lot of weight. 

That number is PSA. 

For decades, PSA has been one of the primary tools used in prostate cancer screening. It remains valuable, but PSA is not a direct test for cancer, and the conversation around screening today is helping physicians better understand where it may have blind spots. 

Early prostate cancer usually causes no symptoms, and in some men, the disease may be present even when a PSA blood test does not raise an obvious red flag. That means waiting until something feels wrong can mean waiting too long. 

It’s not about replacing PSA. It’s about adding another perspective. How much can a PSA test really tell you, and what can additional imaging reveal? 

Newer research is looking beyond PSA alone and examining how prostate MRI can add another piece of information. PSA measures a signal, while MRI looks at the prostate tissue. Together, they may provide a more complete picture of prostate health and help determine when further evaluation may be appropriate.

Why prostate cancer screening matters even when you feel healthy

Prostate cancer is common. About 1 in 8 men will be diagnosed with prostate cancer during his lifetime, and risk increases with age. Family history, race and certain inherited genetic changes can also affect risk. But here’s what makes early detection challenging: 

Early prostate cancer usually doesn’t cause symptoms. 

You can feel healthy and still have disease developing in the prostate. That’s why early detection of prostate cancer is so critical. Screening is about looking for signs of disease before symptoms give you a reason to. 

What does a PSA test actually tell you?

PSA stands for prostate-specific antigen, a protein made by cells in the prostate. A PSA test measures the amount of protein in your blood. In general, the likelihood of prostate cancer increases as PSA levels rise, which is why PSA can be a useful first step in assessing risk. 

But a PSA test does not directly detect prostate cancer. PSA levels can rise for reasons other than cancer. Benign prostate enlargement and inflammation, for example, can both increase PSA. The opposite can happen, too. 

A man can have prostate cancer even when his PSA level isn’t particularly high. The American Cancer Society notes that PSA testing can produce both false-positive results, an abnormal PSA when cancer isn’t present and false-negative results, when cancer is present despite a PSA result that doesn’t appear abnormal.

Can you have prostate cancer with a low PSA?

Yes.

That’s one reason PSA shouldn’t be treated as a simple cancer-or-no-cancer test.

In the ReIMAGINE study, researchers evaluated abbreviated prostate MRI alongside PSA-based measures. Among 31 men ultimately diagnosed with clinically significant prostate cancer, 15—or 48%—had a PSA below 3 ng/mL. By comparison, 27 of the 31 had a positive screening MRI.

That doesn’t mean PSA doesn’t work.

It means PSA tells us something important, but it doesn’t tell us everything.

What does prostate MRI add?

Rather than relying only on the amount of a protein circulating in the blood, MRI creates detailed images that allow radiologists to look for suspicious areas within the prostate.

Prostate MRI can help identify and localize suspicious areas that may represent clinically significant prostate cancer. Radiologists use a standardized system called PI-RADS to describe how suspicious an area appears, with scores ranging from 1, or very low likelihood of clinically significant cancer, to 5, or very high likelihood.

SimonMed offers advanced prostate MRI with AI-supported analysis and interpretation by subspecialty-trained radiologists. Depending on the reason for the exam and the patient’s clinical history, prostate MRI may be performed with or without IV contrast.

Recent prostate cancer screening studies have also evaluated abbreviated noncontrast biparametric MRI protocols using T2-weighted and diffusion-weighted imaging.

At SimonMed, AI tools support the radiologist by helping analyze prostate MRI findings, while the final interpretation and PI-RADS assessment are made by the radiologist. This combination of advanced technology and subspecialty expertise can provide your healthcare provider with more information to guide appropriate next steps.

Why physicians are looking beyond PSA alone

Researchers are still studying exactly how MRI should fit into prostate cancer screening. But several recent studies are helping clarify what it may add.

PROSA: MRI identified more clinically significant cancers

The PROSA randomized clinical trial compared two screening strategies in asymptomatic men.

One group received noncontrast biparametric MRI regardless of PSA level. The other received MRI only when PSA reached a specified threshold.

Clinically significant prostate cancer was detected in 4.6% of men in the MRI-first group compared with 1.8% in the PSA-triggered MRI group. The relative risk of detecting clinically significant cancer was 2.6 times higher.

The study was relatively small and conducted at a single center, and researchers noted that longer follow-up is needed. But the findings add to growing evidence that MRI may identify meaningful disease that a PSA-triggered pathway alone could miss.

ReIMAGINE: PSA can have blind spots

ReIMAGINE tells a related story.

Among the 31 men diagnosed with clinically significant prostate cancer in the study, nearly half had PSA below 3 ng/mL, while 87% had a positive screening MRI.

Again, that doesn’t make PSA unimportant.

It shows why physicians increasingly have more than one source of information available when evaluating prostate cancer risk.

GÖTEBORG-2: MRI may help make biopsy more selective

Finding more cancer isn’t necessarily the goal.

Some prostate cancers grow so slowly that they may never cause health problems. Detecting these clinically insignificant cancers can lead to additional testing, anxiety and potentially unnecessary treatment.

That’s where the GÖTEBORG-2 trial is especially interesting.

After roughly four years of follow-up, researchers found that using MRI-targeted biopsy and omitting biopsy in men with negative MRI results eliminated more than half of diagnoses of clinically insignificant prostate cancer compared with systematic biopsy.

The bigger goal isn’t simply to diagnose as much prostate cancer as possible.

It’s to become better at identifying the cancers that matter while avoiding unnecessary procedures and diagnoses when possible.

Does an abnormal prostate MRI automatically mean you’ll need a biopsy?

Not necessarily.

An abnormal prostate MRI does not automatically mean you need a biopsy.

MRI provides additional information that your healthcare team can consider alongside PSA levels, PSA history, age, family history and other individual risk factors.

It can help clinicians:

• Identify suspicious areas within the prostate.
• Assess how concerning those areas appear.
• Determine where to target a biopsy when one is appropriate.
• Potentially identify some men who may not benefit from immediate biopsy.

PI-RADS itself does not dictate whether someone should have a biopsy. Clinical history, laboratory results and other factors still matter.

And MRI cannot confirm prostate cancer on its own.

When a tissue diagnosis is needed, biopsy remains necessary to determine whether cancer is actually present and to characterize the cancer.

MRI isn’t about creating more biopsies. It may help make biopsy decisions smarter.

That distinction matters.

In GÖTEBORG-2, MRI-directed biopsy strategies reduced the detection of clinically insignificant cancers compared with systematic biopsy.

In other words, imaging can help provide more information about where suspicion exists and how concerning a finding may be before tissue is sampled.

Who should talk with their provider about prostate MRI?

There isn’t a universal recommendation that every man over a certain age should receive a prostate MRI.

Prostate cancer screening should be individualized.

Depending on your individual risk, prostate MRI may be worth discussing with your healthcare provider if you have:

• A rising or borderline PSA
• A family history of prostate cancer
• Other factors that increase your risk of prostate cancer
• A previous negative biopsy but continued clinical concern
• Questions about whether PSA alone provides enough information about your risk 

Screening conversations themselves may need to begin earlier for men at elevated risk. For example, the American Cancer Society recommends discussing screening around age 50 for men at average risk, age 45 for men at higher risk—including African American men and men with a first-degree relative diagnosed before age 65—and age 40 for some men at even higher risk.

Your age, overall health, family history, individual risk factors and PSA history all help determine what makes sense for you.

The bigger shift: from reacting to disease to seeing risk earlier

For much of modern medicine, imaging has been used after symptoms appear to answer a familiar question: What’s wrong?

Advances in imaging are creating another opportunity: to look for meaningful disease earlier, sometimes before symptoms develop.

Prostate MRI is one example of that evolution.

It doesn’t make PSA obsolete. It doesn’t eliminate the need for biopsy when tissue diagnosis is appropriate. And it isn’t the right screening test for every man.

What it can provide is another source of information.

That’s closely aligned with SimonMed’s broader approach to health technology: making advanced diagnostic information more accessible so people and their clinicians have more opportunity to identify disease earlier and make informed decisions about what comes next.

Know more about your prostate health

PSA has played an important role in prostate cancer screening for decades, and it continues to provide valuable information. But that isn’t the whole story. 

Prostate cancer can sometimes develop without markedly elevated PSA levels, while elevated PSA can also occur for reasons unrelated to cancer. MRI offers another way to evaluate risk by allowing radiologists to look directly at prostate tissue and identify suspicious areas that may deserve closer attention. 

PSA provides important information about prostate cancer risk. Prostate MRI can provide another perspective by allowing radiologists to look directly at prostate tissue and identify suspicious areas that may deserve closer evaluation.

Talk with your healthcare provider about your prostate cancer risk and whether prostate MRI may be appropriate for you.

This article is for educational purposes and isn’t a substitute for individualized medical advice, diagnosis or treatment.